Previous Close | 2.8100 |
Open | 3.0600 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 2.9407 - 3.2000 |
52 Week Range | 2.3015 - 9.2900 |
Volume | |
Avg. Volume | 2,089 |
Market Cap | 6.25M |
Beta (5Y Monthly) | 0.46 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.2770 |
Earnings Date | Apr 27, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for AGNPF
VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce it has been invited to present the results from its Phase 2a Study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis (“IPF”) and Chronic Cough, at the 9th American Cough Conference in June, 2023. The American Cough Conference is the world’
VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce additional results from its Phase 2a Study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis (“IPF”) and chronic cough. After further review of the topline data, Ifenprodil was shown to be much more effective at reducing cough in patients
The Power Play by The Market Herald has announced the release of new interviews with First Mining Gold Corp., Algernon Pharmaceuticals, G Mining Ventures, ApartmentLove, and Orvana Minerals on their latest news.